Conor Killmurray

Real-world data regarding the use of tisagenlecleucel and axicabtagene ciloleucel CAR T-cell therapy are reported at 2021 EHA.

Data from a phase 1b trial of the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma display safety and early efficacy.

In an updated analysis of the combination of lenvatinib and pembrolizumab for patients with advanced melanoma efficacy results continue to show a durable response.

Patients with EGFR T790M-positive non–small cell lung cancer who progressed on prior treatment experienced a clinically meaningful efficacy when treated with D-0316.

Patients with heavily pretreated vulvar squamous cell carcinoma experienced responses with pembrolizumab monotherapy in a nonrandomized phase 2 trial, regardless of PD-L1 status.

Data from the phase 2 OVARIO study showed extended progression-free survival benefit of niraparib plus bevacizumab in patients with heavily pretreated advanced ovarian cancer.

Using the single-agent atezolizumab (Tecentriq) plus chemotherapy versus chemotherapy alone to treat patients in the front-line setting with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma (mUC) revealed additional clinical evidence.

Liposomal irinotecan as second-line therapy for SCLC is feasible, safe after frontline platinum therapy failure.

Data presented at the 2021 ASCO Gastrointestinal Cancers Symposium found that health-related quality of life among younger survivors of colorectal cancer is poor and social and functional well-being are also suffering as treatment durations increase.

Frontline pembrolizumab induced clinically meaningful improvements in the health-related quality of life of patients with microsatellite instability-high and/or mismatch repair-deficient metastatic colorectal cancer.

The allogeneic CAR-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, demonstrated clinical responses and manageable toxicity in patients with pretreated large B-cell and follicular lymphomas in the Phase I ALPHA trial.

Utilizing data from the INFORM registry, researchers were able to identify high level priority targets in pediatric patients with cancer utilizing an algorithm that matched them to targeted treatments extending their progression-free survival time and showing the feasibility of this program in a real-world setting.

Those who quit smoking, which can span as far out at 2 years prior to a lung cancer diagnosis, have increased chances of survival, compared with those who continue to smoke.